Tag: Bharat Biotech
India’s one billion vaccinations feat: Stakeholders hail mammoth effort to achieve...
In a historic achievement, the cumulative COVID-19 vaccine doses administered in the country has surpassed the 100-crore milestone........................
Covaxin gets nod for kids aged 2-18 years
The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group
Bharat Biotech unveils first commercial batch of COVAXIN manufactured in Ankleshwar
The vaccine batches manufactured from Ankleshwar facilities in Gujarat will be available for supplies starting September 2021.........................
IVI & Bharat Biotech begin Chikungunya vaccine trials in Costa Rica
Phase II and III trials are funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology (DBT), India.............................
Indian Immunologicals to produce 3-4 million Covaxin drug substance per month
Output of Covaxin drug substance will be 3 to 4 million a month and from December will increase to 10 million a month...........................
Bharat Biotech issues statement to ward off fake news on Covaxin
The company has stated that the fake news and false and misleading narratives result in unintended consequences of creating panic in a large number of people, resulting in vaccine hesitancy.......................
Bharat Biotech’s ROTAVAC 5D® receives WHO prequalification
Prequalification will fast-track procurement and global access of ROTAVAC 5D, the only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume........................
Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19
Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................
COVAXIN pricing based on many factors, says Bharat Biotech as it...
It is emblematic that Bharat Biotech has not sought Indemnity from the Government of India for any adverse events from COVAXIN...................
Bharat Biotech clarifies on the US-FDA’s EUA denial for COVAXIN
As per Bharat Biotech, its US partner, Ocugen has received a recommendation from the FDA to pursue Biologics License Applications (BLA) path for COVAXIN, which is full approval instead of EUA...................